Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2017-09-10 Earnings Release
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
Earnings Release Classification · 90% confidence The document is a press release from two pharmaceutical companies, Ipsen and Exelixis, announcing updated clinical trial results (Phase 2 CABOSUN trial for renal cell carcinoma) presented at a medical conference (ESMO 2017). It details efficacy data (PFS, OS, response rates) and discusses regulatory submissions (sNDA to FDA, dossier to EMA). This type of announcement, focusing on scientific data presentation and subsequent investor/media discussion, is characteristic of an Earnings Release (ER) or a general announcement related to clinical/business updates. Since it is a detailed announcement of results, not just a brief mention, it is more substantial than a simple RPA or RNS. However, it is not a full Annual Report (10-K), a comprehensive Interim Report (IR), or a dedicated Investor Presentation (IP). Given the focus on announcing key financial/operational results (clinical trial outcomes that drive future revenue/strategy) via a press release format, 'Earnings Release' (ER) is the most appropriate fit among the provided codes, as these often include significant operational milestones beyond just quarterly financials. It is a major business update. If 'ER' is interpreted strictly as only quarterly financial results, then 'RNS' (Regulatory Filings/General Announcement) would be the fallback. However, in the context of financial databases, major clinical trial result announcements that impact valuation are often grouped with ERs or IPs. Since it is a formal press release announcing key data and upcoming calls, ER is chosen as the primary classification for a significant business/operational update. FY 2017
2017-09-10 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Earnings Release Classification · 99% confidence The document is a press release dated September 10, 2017, announcing updated clinical trial results (CABOSUN study comparing cabozantinib vs. sunitinib for advanced renal cell carcinoma) presented at the ESMO 2017 congress. It details efficacy data, safety profiles, and mentions regulatory submissions (sNDA to FDA, filing with EMA). This content strongly aligns with an Earnings Release (ER) or a general press release detailing significant operational/clinical updates, rather than a formal regulatory filing like a 10-K or a comprehensive Interim Report (IR). Since it focuses on presenting new clinical data and is structured as a formal announcement from the companies (Ipsen and Exelixis) regarding data presented at a major medical conference, it fits best as an Earnings Release (ER) which often includes key operational/clinical highlights, or potentially a Regulatory Filing (RNS) if it were less detailed. Given the depth of the results presentation and the context of major data disclosure, ER is the most appropriate fit among the options for a company communicating key performance/development milestones outside of mandatory periodic financial reports. It is not a transcript (CT), a management discussion (MDA), or a formal financial supplement (XLSX). FY 2017
2017-09-10 French
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from Ipsen dated September 8, 2017, announcing that the European Medicines Agency (EMA) validated their application for a new indication for Cabometyx® (cabozantinib) for first-line treatment of advanced renal cell carcinoma (aRCC). The text details clinical study results (CABOSUN), regulatory milestones (EMA validation, FDA approval history), and provides background on the disease and the drug. This type of announcement, focusing on regulatory submissions, clinical data presentation, and partnership updates, is characteristic of an Investor Presentation (IP) or a detailed press release that often accompanies such strategic updates, rather than a formal regulatory filing like a 10-K or an Earnings Release (ER). Given the detailed strategic and clinical information presented in a narrative/slide-like format (though presented as text here), 'Investor Presentation' (IP) is the most fitting category, as these documents are designed to convey strategic progress and data to the investment community. It is not a short announcement of a report (RPA/RNS), nor is it a transcript (CT) or a formal financial report (10-K/IR).
2017-09-08 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated September 8, 2017, announcing that Ipsen received validation from the European Medicines Agency (EMA) for a new indication application for Cabometyx®. This type of announcement, detailing regulatory progress, clinical trial data (CABOSUN), and future outlook, is characteristic of an Earnings Release (ER) or a general press release related to corporate/pipeline news. Since it is not a full annual report (10-K), a quarterly report (IR), a transcript (CT), or a specific shareholder document (like DEF 14A or DVA), and it focuses on key operational/regulatory milestones rather than just financial results highlights (ER), it fits best as a general corporate announcement. However, given the options, announcements regarding regulatory milestones and pipeline updates are often categorized under Earnings Release (ER) if they are timely announcements of significant corporate events, or sometimes as Regulatory Filings (RNS) if they are mandatory disclosures. Since this is a proactive press release detailing a major regulatory step (EMA validation) and supporting clinical data, it functions as a significant corporate update. In many databases, such detailed pipeline/regulatory updates are grouped with Earnings Releases or Investor Presentations. Given the structure and content (announcement of a regulatory event and supporting data), it is most closely aligned with an Earnings Release (ER) which often includes operational highlights, or potentially an Investor Presentation (IP) if it were a slide deck, but as a press release, ER is the closest fit for significant corporate news dissemination, though RNS is a possibility if it were purely a mandatory filing. Since it is a detailed announcement of a regulatory milestone, I will classify it as an Earnings Release (ER) as these often contain operational/pipeline news alongside financial context, or RNS as a general regulatory announcement. Given the focus on a specific regulatory validation and clinical data, and the lack of explicit financial summary typical of a pure ER, RNS (Regulatory Filings - general/fallback) is a safer classification for a non-standard, non-financial-summary press release about regulatory progress. However, if we consider the context of major corporate news dissemination, ER is often used. Let's re-evaluate: It is a press release announcing a regulatory validation. This is not a financial result summary (ER), nor a presentation (IP). It is a specific regulatory/pipeline update. This fits well under the general 'Regulatory Filings' (RNS) category as a non-standard disclosure, or potentially a specific type of Investor Relations communication. Given the options, RNS serves as the best catch-all for significant, non-standard regulatory/corporate news releases that aren't explicitly defined elsewhere. I will assign a high confidence to RNS as a general regulatory announcement press release.
2017-09-08 English
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release from Ipsen announcing their participation and the presentation of 16 clinical study abstracts at the European Society of Medical Oncology (ESMO) congress. It provides details on the scientific portfolio, upcoming conference call information, and extensive safety/product information for their oncology drugs. It does not constitute a formal financial report, earnings release, or regulatory filing, but rather a corporate announcement regarding research and development activities and scientific presence at a medical conference. As it does not fit into specific financial categories like 10-K or IR, and is not a simple report publication announcement, it is best classified as a general regulatory/corporate announcement. FY 2017
2017-09-04 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from Ipsen, dated September 4, 2017, announcing that 16 abstracts related to its oncology portfolio (including Onivyde®, Cabometyx®, Somatuline®, and Xermelo®) will be presented at the European Society for Medical Oncology (ESMO 2017) congress. It details the specific abstracts, presentation times, and includes safety information for one of the drugs (ONIVYDE®). This is not a full Annual Report (10-K), an Interim Report (IR), or a standard Earnings Release (ER). It is an announcement about scientific data being presented at a medical conference. This type of announcement, which details research findings and presentations, is best classified as an Investor Presentation (IP) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the focus on presenting clinical data and strategy updates to the investment community (including mentioning a conference call for media and investors), 'Investor Presentation' (IP) is a strong fit, as these press releases often accompany or precede investor briefings about clinical milestones. However, the core content is an announcement of scientific abstracts being presented at a third-party medical meeting (ESMO). While it contains investor-facing elements (conference call announcement), the primary purpose is disseminating research news. In many classification schemes, announcements about data presentations at major medical conferences are often grouped with Investor Presentations (IP) or sometimes Regulatory Filings (RNS) if they don't fit elsewhere. Since it is a detailed announcement about upcoming presentations of clinical data, IP is the most appropriate category among the choices provided, as it serves to inform investors about R&D progress. It is not a Report Publication Announcement (RPA) because it is announcing presentations *at* a conference, not announcing the publication of a formal company report (like a 10-K or IR). The document length is substantial (45k chars), confirming it is more than a brief announcement.
2017-09-04 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.